SavedAdd your journal

Journals / Dokuz Eylül Üniversitesi Tıp Fakültesi Dergisi / 2020 / Cilt: 34 - Sayı: 1

PARADOXICAL PULMONARY SARCOIDOSIS UNDER ETANERCEPT TREATMENT: A CASE REPORT AND REVIEW OF THE LITERATURE

Etanersept tedavisi altında gelişen paradoksal pulmoner sarkoidoz: Olgu sunumu ve literatürün gözden geçirilmesi

Sadettin USLU
Semih GÜLLE
Naciye Sinem GEZER
Sermin ÖZKAL
Fatoş ÖNEN
Pages
59–65
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

We think that the discontinuation of TNFi treatment and secukinumab (anti-IL17A) or other TNFi agents can be used safely in patients who develop paradoxical sarcoidosis during TNFi treatments.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Tumor necrosis factor inhibitor (TNFi) therapies are currently one of the most important treatment options in rheumatic diseases.
📊
Key Findings & Data:Mediastinal lymphadenopathy and central located nodules in both lungs were detected in the 40-year-old male patient who had been using etanercept (50 mg/week subcutaneously) for 3 years with the diagnosis of psoriatic arthritis (PsA).
💡
Conclusion & Impact:We think that the discontinuation of TNFi treatment and secukinumab (anti-IL17A) or other TNFi agents can be used safely in patients who develop paradoxical sarcoidosis during TNFi treatments.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:psöriatik artrit · etanersept · TNFi

Abstract

Tumor necrosis factor inhibitor (TNFi) therapies are currently one of the most important treatment options in rheumatic diseases. However, the use of these agents has been shown to be associated with the development of paradoxical autoimmune reactions. In this case report, we aimed to discuss the patient who developed paradoxical sarcoidosis under etanercept treatment in the light of current literature. Mediastinal lymphadenopathy and central located nodules in both lungs were detected in the 40-year-old male patient who had been using etanercept (50 mg/week subcutaneously) for 3 years with the diagnosis of psoriatic arthritis (PsA). Lymph node biopsy revealed non-caseified granulomatous inflammation. The patient was diagnosed as asymptomatic paradoxical sarcoidosis and etanercept treatment was stopped. PsA clinical activity scores of patient were increased during the 6th month follow-up. Therefore, secukinumab, interleukin 17A inhibitör (anti-IL17A), was started. Nearly complete regression of mediastinal lymph nodes was observed in the first year follow-up of the patient. We think that the discontinuation of TNFi treatment and secukinumab (anti-IL17A) or other TNFi agents can be used safely in patients who develop paradoxical sarcoidosis during TNFi treatments.

Özet

Tümör nekroz faktörü inhibitörü (TNFi) tedavileri günümüzde birçok romatizmal hastalıkta en önemli tedavi basamaklarından birini oluşturmaktadır. Bununla birlikte, bu ajanların kullanımının birçok paradoksal otoimmün hastalığın gelişimi ile ilişkili olduğu gösterilmiştir. Bu vaka sunumunda etanersept tedavisi altında paradoksal sarkoidoz gelişen hastayı güncel literatür eşliğinde tartışmayı amaçladık. Psöriatik artrit (PsA) tanısı ile 3 yıldır etanercept (50 mg/hafta subkutan) kullanan 40 yaşındaki erkek hastanın akciğer görüntülemesinde mediastinal lenfadenopati ve her iki akciğer alanında santral yerleşimli nodüller saptandı. Lenf bezi biopsi sonucu non kazeifiye granülomatöz inflamasyon saptandı. Asemptomatik paradoksal sarkoidoz olarak kabul edilen hastanın etanersept tedavisi sonlandırıldı. Hastanın 6. ay takibinde PsA klinik aktivite skorlarında artış saptandı. Bu nedenle hastaya İnterlökin 17A inhibitörü (anti-IL17A) olan sekükinumab tedavisi başlandı. Hastanın birinci yıl takibinde mediastinal lenf nodlarında tama yakın regresyon izlendi. TNFi tedavisi sırasında paradoksal sarkoidoz gelişen hastalarda mevcut TNFi tedavisinin kesilmesinin ve sekükinumab (anti-IL-17A) veya diğer TNFi tedavilere geçilmesinin uygun olacağını düşünmekteyiz.

🔖

Cite This Article

USLU, S., GÜLLE, S., GEZER, N. S., ÖZKAL, S., ÖNEN, F. (2020). PARADOXICAL PULMONARY SARCOIDOSIS UNDER ETANERCEPT TREATMENT: A CASE REPORT AND REVIEW OF THE LITERATURE. Dokuz Eylül Üniversitesi Tıp Fakültesi Dergisi, Cilt: 34 - Sayı: 1, 59–65. https://ajindex.com/articles/149122

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (9)

  1. Cuchacovich R, Hagan J, Khan T, Richert A, Espinoza LR. Tumor necrosis factor-alpha (TNF-α)-blockade-induced hepatic sarcoidosis in psoriatic arthritis (PsA): case report and review of the literature. Clin Rheumatol. 2011;30(1):133–7.
  2. Ziegenhagen MW, Muller-Quernheim J. The cytokine network in sarcoidosis and its clinical relevance. J Intern Med. 2003;253(1):18–30.
  3. Daien CI, Monnier A, Claudepierre P, Constantin A, Eschard J-P, Houvenagel E, et al. Sarcoid-like granulomatosis in patients treated with tumor necrosis factor blockers: 10 cases. Rheumatology. 2009;48(8):883–6.
  4. Massara A, Cavazzini L, La Corte R, Trotta F. Sarcoidosis Appearing During Anti-Tumor Necrosis Factor α Therapy: A New “Class Effect” Paradoxical Phenomenon. Two Case Reports and Literature Review. Semin Arthritis Rheum. 2010;39(4):313–9. Mengi G. A Rare Adverse Effect of Anti-Tumor Necrosis Factor Alpha Therapy: Sarcoidosis. Arch Rheumatol. 2017;32(1):67–70. Haraoui B. Differentiating the efficacy of the tumor necrosis factor inhibitors. Semin Arthritis Rheum. 2005;34(5):7–11.
  5. Dogra S, Khullar G. Tumor necrosis factor-α antagonists: Side effects and their management. Indian J Dermatology, Venereol Leprol. 2013; 79(7):35. Utz JP, Limper AH, Kalra S, Specks U, Scott JP, Vuk-Pavlovic Z, et al. Etanercept for the Treatment of Stage II and III Progressive Pulmonary Sarcoidosis. Chest. 2003;124(1):177–85.
  6. Jamilloux Y, Cohen-Aubart F, Chapelon-Abric C, Maucort-Boulch D, Marquet A, Pérard L, et al. Efficacy and safety of tumor necrosis factor antagonists in refractory sarcoidosis: A multicenter study of 132 patients. Semin Arthritis Rheum. 2017;47(2):288–94.
  7. Massara A, Cavazzini L, La Corte R, Trotta F. Sarcoidosis Appearing During Anti-Tumor Necrosis Factor (alpha) Therapy: A New “Class Effect” Paradoxical Phenomenon. Two Case Reports and Literature Review. Semin Arthritis Rheum. 2010; 39(4): 313-9.
  8. Cleynen I, Vermeire S. Paradoxical inflammation induced by anti-TNF agents in patients with IBD. Nat Rev Gastroenterol Hepatol. 2012;9(9):496–503.
  9. Conrad C, Di Domizio J, Mylonas A, Belkhodja C, Demaria O, Navarini AA, et al. TNF blockade induces a dysregulated type I interferon response without autoimmunity in paradoxical psoriasis. Nat Commun. 2018;9(1):25. Roux CH, Brocq O, Leccia N, Giacchero D, Breuil V, Albert C, et al. New-onset psoriatic palmoplantaris pustulosis following infliximab therapy: a class effect? J Rheumatol. 2007; 34(2):434–7. Toussirot É, Aubin F. Paradoxical reactions under T